ASML vs MLAB

ASML exhibits strong financial health with a Piotroski F-Score of 4/9, indicating stable fundamentals despite not reaching the 'strong' threshold. The company's robust profitability metrics—especially a 50.46% ROE and 29.42% profit margin—underscore its operational excellence. While the current price of $1,345.69 trades at a premium to both the Graham Number ($193.99) and Intrinsic Value ($507.83), this is justified by exceptional growth prospects and dominant market positioning in semiconductor equipment. The recent earnings beat rate of 50% over the last four quarters and consistent positive surprises support a bullish outlook. The absence of an Altman Z-Score does not indicate distress risk, as the company maintains a low debt-to-equity ratio (0.24) and strong liquidity. Price trades at a 28.2% premium to fair value estimate ($1050.00), limiting near-term upside from a valuation perspective.

MLAB exhibits a stable financial health profile with a Piotroski F-Score of 6/9, but it is fundamentally disconnected from its valuation. The stock trades at a massive premium to its Graham Number ($22.23) and Intrinsic Value ($4.55), with a trailing P/E of 150.54. While the forward P/E of 18.15 suggests an expected earnings recovery, the current dividend payout ratio of 98.46% is unsustainable. Long-term price performance is severely negative, indicating a persistent lack of value creation over a 5-year horizon.